

Bernard Combe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9097137/publications.pdf>

Version: 2024-02-01

286
papers

37,045
citations

8755

77
h-index

3595

187
g-index

317
all docs

317
docs citations

317
times ranked

24073
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of Cancer After Initiation of Targeted Therapies in Patients With Rheumatoid Arthritis and a Prior Cancer: Systematic Review With <scp>Meta-Analysis</scp>. Arthritis Care and Research, 2023, 75, 260-271.	1.5	7
2	Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept. Rheumatology, 2022, 61, 953-962.	0.9	15
3	The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies. Arthritis Research and Therapy, 2022, 24, 11.	1.6	6
4	Impact of multimorbidity on disease modifying antirheumatic drug therapy in early rheumatoid arthritis: Data from the ESPOIR cohort. Joint Bone Spine, 2022, 89, 105326.	0.8	0
5	Validation in the ESPOIR cohort of vitamin K-dependent protein S (PROS) as a potential biomarker capable of predicting response to the methotrexate/etanercept combination. Arthritis Research and Therapy, 2022, 24, 72.	1.6	0
6	Exploring the disparity between inflammation and disability in the 10-year outcomes of people with rheumatoid arthritis. Rheumatology, 2022, 61, 4687-4701.	0.9	5
7	Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure. Annals of the Rheumatic Diseases, 2022, 81, 944-950.	0.5	2
8	Positive impact on 10-year outcome of the window of opportunity for conventional synthetic DMARDs in rheumatoid arthritis: results from the ESPOIR cohort. RMD Open, 2022, 8, e002040.	1.8	0
9	Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results. Clinical Rheumatology, 2022, 41, 3035-3047.	1.0	4
10	Impact of disease activity and treatments on ovarian reserve in patients with rheumatoid arthritis in the ESPOIR cohort. Rheumatology, 2021, 60, 1863-1870.	0.9	5
11	Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries. Annals of the Rheumatic Diseases, 2021, 80, 518-526.	0.5	54
12	Time to initiation of biologic disease-modifying antirheumatic drugs in the French cohort ESPOIR. Joint Bone Spine, 2021, 88, 105060.	0.8	6
13	Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2). Rheumatology and Therapy, 2021, 8, 199-217.	1.1	8
14	Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early rheumatoid arthritis. Rheumatology, 2021, 60, 3738-3746.	0.9	24
15	Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis. Expert Review of Clinical Immunology, 2021, 17, 85-100.	1.3	14
16	Evaluation of the impact of a nurse-led program of patient self-assessment and self-management in axial spondyloarthritis: results of a prospective, multicentre, randomized, controlled trial (COMEDSPA). Rheumatology, 2021, 60, 888-895.	0.9	21
17	Disease-modifying drug retention rate according to patient age in patients with early rheumatoid arthritis: analysis of the ESPOIR cohort. Rheumatology International, 2021, 41, 879-885.	1.5	5
18	Cytomegalovirus infection: friend or foe in rheumatoid arthritis?. Arthritis Research and Therapy, 2021, 23, 16.	1.6	8

#	ARTICLE	IF	CITATIONS
19	Head-to-head trials in inflammatory arthritis. <i>Joint Bone Spine</i> , 2021, 88, 105004.	0.8	0
20	Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies. <i>Arthritis Research and Therapy</i> , 2021, 23, 41.	1.6	12
21	Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials. <i>Arthritis Research and Therapy</i> , 2021, 23, 119.	1.6	13
22	OP0183â€¦IDENTIFICATION OF A SUBGROUP OF PEOPLE WITH RHEUMATOID ARTHRITIS CHARACTERISED BY HIGH DISABILITY OVER 10 YEARS, DESPITE LOW INFLAMMATION: RESULTS FROM TWO EUROPEAN PROSPECTIVE COHORT STUDIES. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 110.2-111.	0.5	0
23	POS0658â€¦GEOGRAPHIC VARIATION OF EFFICACY IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 570-571.	0.5	0
24	POS0657â€¦GEOGRAPHIC VARIATION OF SAFETY IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 569.2-570.	0.5	0
25	POS0654â€¦IMPACT OF CONCOMITANT GLUCOCORTICOIDS ON THE CLINICAL EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: AN AD HOC ANALYSIS OF DATA FROM THREE PHASE 3 STUDIES. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 567-568.	0.5	0
26	Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort. <i>Rheumatology</i> , 2021, 60, 5073-5079.	0.9	12
27	COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e419-e426.	2.2	211
28	The DIGICOD cohort: A hospital-based observational prospective cohort of patients with hand osteoarthritisâ€”methodology and baseline characteristics of the population. <i>Joint Bone Spine</i> , 2021, 88, 105171.	0.8	23
29	Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52. <i>Clinical Rheumatology</i> , 2021, 40, 4943-4954.	1.0	2
30	Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 848-858.	0.5	123
31	Lymphoma complicating rheumatoid arthritis: results from a French case-control study. <i>RMD Open</i> , 2021, 7, .	1.8	0
32	Cardiovascular events and change in cholesterol levels in patients with rheumatoid arthritis treated with tocilizumab: data from the REGATE Registry. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 501-507.	0.4	1
33	Change in MRI in patients with spondyloarthritis treated with anti-TNF agents: systematic review of the literature and meta-analysis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 242-252.	0.4	1
34	Trajectories in early rheumatoid arthritis related fatigue over 10 years: results from the ESPOIR cohort. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	0
35	Lymphoma complicating rheumatoid arthritis: results from a French caseâ€”control study. <i>RMD Open</i> , 2021, 7, e001698.	1.8	13
36	Change in MRI in patients with spondyloarthritis treated with anti-TNF agents: systematic review of the literature and meta-analysis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 242-252.	0.4	5

#	ARTICLE	IF	CITATIONS
37	Cardiovascular events and change in cholesterol levels in patients with rheumatoid arthritis treated with tocilizumab: data from the REGATE Registry. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 501-507.	0.4	6
38	Low Influenza, Pneumococcal and Diphtheria/Tetanus/Poliomyelitis Vaccine Coverage in Patients with Primary Sjögren's Syndrome: A Cross-Sectional Study. <i>Vaccines</i> , 2020, 8, 3.	2.1	9
39	An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases. <i>Rheumatology</i> , 2020, 59, 1842-1852.	0.9	13
40	Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study. <i>RMD Open</i> , 2020, 6, e000991.	1.8	8
41	Predictors of fatigue and persistent fatigue in early rheumatoid arthritis: a longitudinal observational study, data from the ESPOIR cohort. <i>Scandinavian Journal of Rheumatology</i> , 2020, 49, 259-266.	0.6	11
42	EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 851-858.	0.5	204
43	Evaluation of the impact of a nurse-led program of systematic screening of comorbidities in patients with axial spondyloarthritis: The results of the COMEDSPA prospective, controlled, one year randomized trial. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 701-708.	1.6	11
44	Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 14.	1.6	27
45	Reduced progression of bone erosion in cytomegalovirus seropositive rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2020, 22, 13.	1.6	4
46	Association Between Vitamin D Deficiency and Disease Activity, Disability, and Radiographic Progression in Early Rheumatoid Arthritis: The ESPOIR Cohort. <i>Journal of Rheumatology</i> , 2020, 47, 1624-1628.	1.0	18
47	Glucocorticoids in rheumatoid arthritis: current status and future studies. <i>RMD Open</i> , 2020, 6, e000536.	1.8	89
48	Referring early arthritis patients within 6 weeks versus 12 weeks after symptom onset: an observational cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e332-e338.	2.2	9
49	THU0207...SUSTAINABILITY OF RESPONSE TO UPADACITINIB AS MONOTHERAPY OR IN COMBINATION AMONG PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DMARDS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 327.1-328.	0.5	0
50	FRI0131...SUSTAINABILITY OF RESPONSE BETWEEN UPADACITINIB AND ADALIMUMAB AMONG PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO METHOTREXATE. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 647.1-648.	0.5	0
51	La présence de diabète lors du diagnostic de la polyarthrite rhumatoïde est un facteur indépendant de mauvais résultats: données de la cohorte ESPOIR sur les polyarthrites récentes. <i>Revue Du Rhumatisme (Edition Française)</i> , 2019, 86, 534-536.	0.0	0
52	Shifting from a Rheumatologic Point of View toward Patient-centered Care in Rheumatoid Arthritis with an Integrated Management of Comorbidities. <i>Journal of Rheumatology</i> , 2019, 46, 545-547.	1.0	7
53	Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. <i>BMJ: British Medical Journal</i> , 2019, 364, l67.	2.4	76
54	Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort. <i>Arthritis Research and Therapy</i> , 2019, 21, 140.	1.6	23

#	ARTICLE	IF	CITATIONS
55	Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1135-1138.	0.5	12
56	SAT0151â€¦TIME TO INITIATION OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE FRENCH COHORT ESPOIR. , 2019, , .		0
57	THU0172â€¦LUPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS: RESULTS AT 60 WEEKS FROM THE SELECT-BEYOND STUDY. , 2019, , .		0
58	AB0421â€¦METHOTREXATE COMPLIANCE AMONG PATIENTS WITH CHRONIC INFLAMMATORY DISEASE OR CONNECTIVE TISSUE DISEASE. , 2019, , .		0
59	Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort. <i>Arthritis Research and Therapy</i> , 2019, 21, 243.	1.6	13
60	Update of French society for rheumatology recommendations for managing rheumatoid arthritis. <i>Joint Bone Spine</i> , 2019, 86, 135-150.	0.8	90
61	Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteenâ€¦Week Resultsâ€¦From a Phase III Randomized, Doubleâ€¦Blind, Placeboâ€¦Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors. <i>Arthritis and Rheumatology</i> , 2019, 71, 599-611.	2.9	142
62	Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 967-975.	1.6	46
63	Response to: â€œMetabolic and cardiovascular benefits of hydroxychloroquine: exploration in a wider population at high CV riskâ€™ by Pareek <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e22-e22.	0.5	1
64	Relevance and feasibility of a systematic screening of multimorbidities in patients with chronic inflammatory rheumatic diseases. <i>Joint Bone Spine</i> , 2019, 86, 49-54.	0.8	21
65	The Reference Site Collaborative Network of the European Innovation Partnership on Active and Healthy Ageing. <i>Translational Medicine @ UniSa</i> , 2019, 19, 66-81.	0.8	11
66	Diabetes at the time of rheumatoid arthritis diagnosis is an independent predictor of pejorative outcomes: Data from the early arthritis ESPOIR cohort. <i>Joint Bone Spine</i> , 2018, 85, 773-775.	0.8	4
67	Efficacy and safety of biological DMARDs modulating B cells in primary SjÃ¶rgren's syndrome: Systematic review and meta-analysis. <i>Joint Bone Spine</i> , 2018, 85, 15-22.	0.8	34
68	Poor efficacy of TNF inhibitors in non-radiographic axial spondyloarthritis in the absence of objective signs: A bicentric retrospective study. <i>Joint Bone Spine</i> , 2018, 85, 461-468.	0.8	11
69	Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 98-103.	0.5	164
70	Response to: â€œCardiovascular effects of hydroxychloroquine: a systematic review and meta-analysisâ€™ by Mathieu <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e66-e66.	0.5	0
71	SAT0569â€¦Impact of bariatric surgery on rheumatic diseases: a systematic review and meta-analysis. , 2018, , .		0
72	Risk of fracture and low bone mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis. <i>Osteoporosis International</i> , 2018, 29, 2389-2397.	1.3	62

#	ARTICLE	IF	CITATIONS
73	Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. <i>Lancet</i> , The, 2018, 391, 2513-2524.	6.3	316
74	OP0066...Risk of fracture and low mineral density in adults with inflammatory bowel diseases. a systematic literature review with meta-analysis. , 2018, , .		1
75	FR10106...Impact of biological and targeted synthetic dmards on work in patients with chronic inflammatory arthritis : a meta analysis of randomised controlled trials and controlled cohorts. , 2018, , .		1
76	Effects of biologic disease-modifying anti-rheumatic drugs on the radiographic progression of rheumatoid arthritis: a systematic literature review. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 658-667.	0.4	12
77	A randomised, double-blind, placebo-controlled study assessing the efficacy of high doses of vitamin D on functional disability in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 1056-1060.	0.4	16
78	Comparison of modified disease-activity scores with original composite scores for prediction of structural damages in rheumatoid arthritis: Data from the ESPOIR cohort. <i>Joint Bone Spine</i> , 2017, 84, 111-112.	0.8	0
79	Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry. <i>Rheumatology</i> , 2017, 56, kew476.	0.9	10
80	Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 694-700.	0.5	83
81	Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1797-1802.	0.5	52
82	2016 update of the EULAR recommendations for the management of early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 948-959.	0.5	393
83	Non-pharmacological and pharmacological interventions in patients with early arthritis: a systematic literature review informing the 2016 update of EULAR recommendations for the management of early arthritis. <i>RMD Open</i> , 2017, 3, e000404.	1.8	43
84	Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the EULAR recommendations for the management of early arthritis. <i>RMD Open</i> , 2017, 3, e000406.	1.8	41
85	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.5	3,366
86	EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 491-496.	0.5	209
87	Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review. <i>Journal of Rheumatology</i> , 2017, 44, 773-779.	1.0	3
88	Biologic Disease-modifying Antirheumatic Drug (bDMARD)-induced Neutropenia: A Registry from a Retrospective Cohort of Patients with Rheumatic Diseases Treated with 3 Classes of Intravenous bDMARD. <i>Journal of Rheumatology</i> , 2017, 44, 844-849.	1.0	12
89	Chikungunya Virus-Associated Disease. <i>Current Rheumatology Reports</i> , 2017, 19, 69.	2.1	38
90	Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohort. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 2054-2060.	0.5	21

#	ARTICLE	IF	CITATIONS
91	Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE. <i>Rheumatology</i> , 2017, 56, 1746-1754.	0.9	49
92	Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the "ORA" registry. <i>RMD Open</i> , 2017, 3, e000515.	1.8	14
93	SAT0189...Factors influencing the prescription of tocilizumab alone or in combination with dmards in rheumatoid arthritis patients in a real life setting. pooled analysis of 3 observational studies. , 2017, , .		0
94	Improvement of fatigue in patients with rheumatoid arthritis treated with biologics: relationship with sleep disorders, depression and clinical efficacy. A prospective, multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 85-92.	0.4	20
95	TNF inhibitors increase fat mass in inflammatory rheumatic disease: a systematic review with meta-analysis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 337-343.	0.4	9
96	Management of dyslipidaemia in high-risk patients with recent-onset rheumatoid arthritis: targets still not met despite specific recommendations. Results from the ESPOIR cohort during the first five years of follow-up. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 296-302.	0.4	10
97	A proliferation inducing ligand (APRIL) promotes IL-10 production and regulatory functions of human B cells. <i>Journal of Autoimmunity</i> , 2016, 73, 64-72.	3.0	60
98	Factors associated with a bad functional prognosis in early inflammatory back pain: results from the DESIR cohort. <i>RMD Open</i> , 2016, 2, e000204.	1.8	16
99	L'association abatacept plus méthotrexate permet d'atteindre un nouveau la mission, de manière efficace et bien tolérée, après la reprise du traitement pour poussées inflammatoires chez des patients atteints de polyarthrite rhumatoïde primaire. <i>Revue Du Rhumatisme (Edition Française)</i> , 2016, 83, A43-A44.	0.0	0
100	Prediction of Remission in a French Early Arthritis Cohort by RAPID3 and other Core Data Set Measures, but Not by the Absence of Rheumatoid Factor, Anticitrullinated Protein Antibodies, or Radiographic Erosions. <i>Journal of Rheumatology</i> , 2016, 43, 1285-1291.	1.0	26
101	Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab. <i>Rheumatology</i> , 2016, 55, 1466-1476.	0.9	20
102	Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials. <i>Journal of Rheumatology</i> , 2016, 43, 1063-1067.	1.0	29
103	Clinical association of mixed connective tissue disease and granulomatosis with polyangiitis: a case report and systematic screening of anti-U1RNP and anti-PR3 auto-antibody double positivity in ten European hospitals. <i>Immunologic Research</i> , 2016, 64, 1243-1246.	1.3	7
104	Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. <i>Lancet, The</i> , 2016, 388, 2763-2774.	6.3	144
105	FRI0219...Risk Factors of Severe Infections in Patients with Rheumatoid Arthritis Treated with Tocilizumab in The French Registry Regate (Registry "Roactemra). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 511.2-511.	0.5	0
106	Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data. <i>RMD Open</i> , 2016, 2, e000245.	1.8	15
107	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 3-15.	0.5	1,114
108	Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry. <i>Rheumatology</i> , 2016, 55, 874-882.	0.9	49

#	ARTICLE	IF	CITATIONS
109	SAT0048â€¦Identification of Genes Regulating Trail-Induced Apoptosis in Rheumatoid Arthritis Fibroblasts-Like Synoviocytes (RA FLS). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 665.2-665.	0.5	0
110	Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study. <i>RMD Open</i> , 2015, 1, e000037.	1.8	17
111	Operational definition of Active and Healthy Ageing (AHA): A conceptual framework. <i>Journal of Nutrition, Health and Aging</i> , 2015, 19, 955-960.	1.5	85
112	Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts. <i>RMD Open</i> , 2015, 1, e000128.	1.8	17
113	Early lessons from the recent-onset rheumatoid arthritis cohort ESPOIR. <i>Joint Bone Spine</i> , 2015, 82, 13-17.	0.8	32
114	Identification of secreted phosphoprotein 1 gene as a new rheumatoid arthritis susceptibility gene. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e19-e19.	0.5	24
115	High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis. <i>Rheumatology</i> , 2015, 54, 601-608.	0.9	36
116	Reasons for non-vaccination in French rheumatoid arthritis and spondyloarthritis patients. <i>Rheumatology</i> , 2015, 54, 748-750.	0.9	37
117	The effect on treatment response of fibromyalgic symptoms in early rheumatoid arthritis patients: results from the ESPOIR cohort. <i>Rheumatology</i> , 2015, 54, 2166-2170.	0.9	18
118	Clinical presentation of patients suffering from recent onset chronic inflammatory back pain suggestive of spondyloarthritis: The DESIR cohort. <i>Joint Bone Spine</i> , 2015, 82, 345-351.	0.8	92
119	Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 724-729.	0.5	52
120	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 963-969.	0.5	36
121	PrÃ©sentation clinique des patients souffrant de rachialgie inflammatoire chronique rÃ©cente Ã©vocatrice de spondyloarthriteÂ: la cohorte Desir. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2015, 82, 378-385.	0.0	0
122	Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as prognostic factors in rheumatoid arthritis: results from the ESPOIR cohort. <i>Arthritis Research and Therapy</i> , 2015, 17, 193.	1.6	7
123	Targeting the Fas/FasL system in Rheumatoid Arthritis therapy: Promising or risky?. <i>Cytokine</i> , 2015, 75, 228-233.	1.4	24
124	Evaluation of Serum Interleukinâ€6 Level as a Surrogate Marker of Synovial Inflammation and as a Factor of Structural Progression in Early Rheumatoid Arthritis: Results From a French National Multicenter Cohort. <i>Arthritis Care and Research</i> , 2015, 67, 905-912.	1.5	55
125	Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature. <i>Rheumatology</i> , 2015, 54, 915-926.	0.9	60
126	Psychological distress over time in early rheumatoid arthritis: results from a longitudinal study in an early arthritis cohort. <i>Rheumatology</i> , 2015, 54, 520-527.	0.9	34

#	ARTICLE	IF	CITATIONS
127	THU0264...In Early Rheumatoid Arthritis (Espoir Cohort), Serum CCL19 Level is Associated with Disease Activity, Autoantibody Secretion and 3-Year Radiographic Progression: Data from the Espoir Cohort. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 274.2-274.	0.5	0
128	Repeated Anticitrullinated Protein Antibody and Rheumatoid Factor Assessment Is Not Necessary in Early Arthritis: Results from the ESPOIR Cohort. <i>Journal of Rheumatology</i> , 2014, 41, 41-46.	1.0	13
129	<i>SPP1</i>s9138 variant contributes to the severity of radiological damage in anti-citrullinated protein autoantibody-negative rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1840-1843.	0.5	13
130	FR10048...Prevalence of Tuberculosis in Early Arthritis and Early Spondyloarthritis Increased in Comparison to the General Population - Results from the ESPOIR and DESIR Cohorts: Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 398.2-399.	0.5	0
131	Efficacy and Safety of Rituximab in Elderly Patients With Rheumatoid Arthritis Enrolled in a French Society of Rheumatology Registry. <i>Arthritis Care and Research</i> , 2014, 66, 1289-1295.	1.5	37
132	Effect of Methotrexate, Anti-Tumor Necrosis Factor \pm , and Rituximab on the Immune Response to Influenza and Pneumococcal Vaccines in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. <i>Arthritis Care and Research</i> , 2014, 66, 1016-1026.	1.5	248
133	Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice. <i>Joint Bone Spine</i> , 2014, 81, 352-359.	0.8	39
134	Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis. <i>Joint Bone Spine</i> , 2014, 81, 6-14.	0.8	85
135	Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. <i>Joint Bone Spine</i> , 2014, 81, 215-221.	0.8	79
136	Prevalence and concordance of early and sustained remission assessed by various validated indices in the early arthritis "ESPOIR" cohort. <i>Joint Bone Spine</i> , 2014, 81, 409-415.	0.8	21
137	Regulatory B10 Cells Are Decreased in Patients With Rheumatoid Arthritis and Are Inversely Correlated With Disease Activity. <i>Arthritis and Rheumatology</i> , 2014, 66, 2037-2046.	2.9	132
138	Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2014, 371, 1781-1792.	13.9	169
139	Association of Anticyclic Citrullinated Peptide Antibodies and/or Rheumatoid Factor Status and Clinical Presentation in Early Arthritis: Results from the ESPOIR Cohort. <i>Journal of Rheumatology</i> , 2014, 41, 1614-1622.	1.0	17
140	Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2094-2100.	0.5	45
141	Taux de r�tention de lâ™adalimumab, de lâ™�tanercept et de lâ™infliximab en 1re ou 2e ligne de bioth�rapie chez les patients atteints de polyarthrite rhumato�de en pratique courante. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2014, 81, 483-490.	0.0	0
142	Reply to Talarico et al.'s comment: "Rate of serious infections in patients with rheumatoid arthritis receiving tumor necrosis factor (TNF)-alpha antagonist: A prospective observational study". <i>Joint Bone Spine</i> , 2014, 81, 379-380.	0.8	0
143	Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis. <i>Joint Bone Spine</i> , 2014, 81, 287-297.	0.8	115
144	Recommandations de la Soci�t� fran�aise de rhumatologie pour la prise en charge de la polyarthrite rhumato�de. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2014, 81, 303-312.	0.0	10

#	ARTICLE	IF	CITATIONS
145	Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1477-1486.	0.5	23
146	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 492-509.	0.5	1,688
147	AB0438â€¦Efficacy and Safety of Tabalumab, an Anti-B Cell Activating Factor Monoclonal Antibody, in Patients with Rheumatoid Arthritis WHO HAD an Inadequate Response to Tnf-Alpha Inhibitors: Results from A Phase 3 Multicenter, Randomized, Double-Blind Study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 952.3-953.	0.5	0
148	THU0485â€¦The SPP1 Rs9138 Variant Contributes to the Severity of Radiologic Damage in Acpa-Negative Rheumatoid Arthritis: Results from the ESPOIR and Leiden EAC Cohorts. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 351.1-351.	0.5	0
149	ESPOIR and the French database management: what have we learned from the first years of follow-up?. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, S-153-7.	0.4	1
150	The two directions of TNF-related apoptosis-inducing ligand in rheumatoid arthritis. <i>Cytokine</i> , 2013, 63, 81-90.	1.4	15
151	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 482-492.	0.5	102
152	GUEPARD treat-to-target strategy is significantly more efficacious than ESPOIR routine care in early rheumatoid arthritis according to patient-reported outcomes and physician global estimate. <i>Rheumatology</i> , 2013, 52, 1890-1897.	0.9	12
153	Defining erosive disease typical of RA in the light of the ACR/EULAR 2010 criteria for rheumatoid arthritis; results of the data driven phase. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 590-595.	0.5	18
154	EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 479-481.	0.5	114
155	Association of Tobacco Exposure and Reduction of Radiographic Progression in Early Rheumatoid Arthritis: Results From a French Multicenter Cohort. <i>Arthritis Care and Research</i> , 2013, 65, 1899-1906.	1.5	38
156	Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1026-1031.	0.5	193
157	Potential Classification Criteria for Rheumatoid Arthritis After Two Years: Results From a French Multicenter Cohort. <i>Arthritis Care and Research</i> , 2013, 65, 1227-1234.	1.5	16
158	Firstâ€¦Year Radiographic Progression as a Predictor of Further Progression in Early Arthritis: Results of a Large National French Cohort. <i>Arthritis Care and Research</i> , 2013, 65, 1907-1915.	1.5	33
159	Can Remission in Rheumatoid Arthritis Be Assessed Without Laboratory Tests or a Formal Joint Count? Possible Remission Criteria Based on a Self-report RAPID3 Score and Careful Joint Examination in the ESPOIR Cohort. <i>Journal of Rheumatology</i> , 2013, 40, 386-393.	1.0	25
160	Value of high-sensitivity C-reactive protein for classification of early axial spondyloarthritis: results from the DÉSIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 785-786.	0.5	4
161	Five-year Favorable Outcome of Patients with Early Rheumatoid Arthritis in the 2000s: Data from the ESPOIR Cohort. <i>Journal of Rheumatology</i> , 2013, 40, 1650-1657.	1.0	38
162	SAT0084â€¦Effects of different steroid doses on adverse events and radiographic progression of certolizumab pegol-treated rheumatoid arthritis patients:. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 498.2-498.	0.5	2

#	ARTICLE	IF	CITATIONS
163	THU0192â€¦5-Year Results from the Rapid 1 Trial and Open-Label Extension: Long-Term Safety and Efficacy of Certolizumab Pegol in Combination with Methotrexate in the Treatment of Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A228.2-A229.	0.5	5
164	THU0173â€¦Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice: The Maintain Study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A221.4-A222.	0.5	2
165	FRI0245â€¦Prospective follow-up of tocilizumab treatment in 1100 patients with refractory rheumatoid arthritis: tolerance data from the french registry regate (registry â€œroactemra). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A456.3-A457.	0.5	2
166	FRI0173â€¦Gastrointestinal perforations with certolizumab PEGOL. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 370.2-370.	0.5	2
167	Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: results from the ESPOIR early synovitis cohort. <i>Rheumatology</i> , 2012, 51, 1648-1654.	0.9	13
168	Combination etanercept and methotrexate provides better disease control in very early (>4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 989-992.	0.5	74
169	Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the Oencia and Rheumatoid Arthritisâ€™ registry. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1815-1819.	0.5	117
170	Level of agreement of the 1987 ACR and 2010 ACR/EULAR rheumatoid arthritis classification criteria: an analysis based on ESPOIR cohort data. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 386-389.	0.5	50
171	Influence of replacing tuberculin skin test with ex vivo interferon Î³ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1783-1790.	0.5	81
172	Effect of adherence to European treatment recommendations on early arthritis outcome: data from the ESPOIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1803-1808.	0.5	26
173	Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 862-868.	0.5	143
174	Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort. <i>Arthritis Research and Therapy</i> , 2012, 14, R249.	1.6	61
175	Validation of ACR/EULAR definition of remission in rheumatoid arthritis from RA practice: the ESPOIR cohort. <i>Arthritis Research and Therapy</i> , 2012, 14, R156.	1.6	27
176	Lâ€™apport et les indications des biothÃ©rapies dans les rhumatismes inflammatoires. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2012, 196, 1279-1293.	0.0	0
177	Understanding emerging treatment paradigms in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2011, 13, S3.	1.6	46
178	American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 404-413.	0.5	657
179	Rapid Improvement in the Signs and Symptoms of Rheumatoid Arthritis Following Certolizumab Pegol Treatment Predicts Better Longterm Outcomes: Post-hoc Analysis of a Randomized Controlled Trial. <i>Journal of Rheumatology</i> , 2011, 38, 990-996.	1.0	39
180	The DESIR cohort: A 10-year follow-up of early inflammatory back pain in France: Study design and baseline characteristics of the 708 recruited patients. <i>Joint Bone Spine</i> , 2011, 78, 598-603.	0.8	204

#	ARTICLE	IF	CITATIONS
181	The new classification criteria for rheumatoid arthritis and their impact on therapeutic decisions. <i>Joint Bone Spine</i> , 2011, 78, 539-541.	0.8	5
182	Arthritis after infection with Chikungunya virus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 337-346.	1.4	45
183	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Arthritis and Rheumatism</i> , 2011, 63, 573-586.	6.7	864
184	Mechanisms and clinical relevance of TRAIL-triggered responses in the synovial fibroblasts of patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2011, 63, 904-913.	6.7	21
185	B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: A six-month, national, multicenter, open-label study. <i>Arthritis and Rheumatism</i> , 2011, 63, 933-938.	6.7	129
186	Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: Data from the Étude et Suivi des Polyarthrites		

#	ARTICLE	IF	CITATIONS
199	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 638-643.	0.5	203
200	Early referral to the rheumatologist for early arthritis patients: evidence for suboptimal care. Results from the ESPOIR cohort. <i>Rheumatology</i> , 2010, 49, 147-155.	0.9	31
201	Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 987-994.	0.5	126
202	Hormonal replacement therapy may reduce the risk for RA in women with early arthritis who carry HLA-DRB1 *01 and/or *04 alleles by protecting against the production of anti-CCP: results from the ESPOIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1683-1686.	0.5	29
203	Rheumatoid Arthritis of the Hand: Monitoring with a Simplified MR Imaging Scoring Methodâ€”Preliminary Assessment. <i>Radiology</i> , 2010, 256, 863-869.	3.6	23
204	Tumor Necrosis Factor-Î± Blockers in SAPHO Syndrome: Table 1.. <i>Journal of Rheumatology</i> , 2010, 37, 1699-1704.	1.0	100
205	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 964-975.	0.5	1,429
206	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Methodological Report Phase I. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1589-1595.	0.5	152
207	Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1629-1635.	0.5	296
208	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1580-1588.	0.5	2,994
209	Treating rheumatoid arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 631-637.	0.5	1,711
210	Impact of dosing on treatment with TNF inhibitors: managing dose adjustment. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, S13-7.	0.4	0
211	Progression in early rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 59-69.	1.4	74
212	Non-drug treatment (excluding surgery) in rheumatoid arthritis: Clinical practice guidelines. <i>Joint Bone Spine</i> , 2009, 76, 691-698.	0.8	107
213	Pharmacological treatment (biotherapy excluded) of peripheral psoriatic arthritis: Development of recommendations for clinical practice based on data from the literature and experts opinion. <i>Joint Bone Spine</i> , 2009, 76, 524-531.	0.8	15
214	Prognosis and follow-up of psoriatic arthritis with peripheral joint involvement: Development of recommendations for clinical practice based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2009, 76, 540-546.	0.8	8
215	Diagnosis of peripheral psoriatic arthritis: Recommendations for clinical practice based on data from the literature and experts opinion. <i>Joint Bone Spine</i> , 2009, 76, 532-539.	0.8	19
216	A report of 21 cases of rheumatoid arthritis following Chikungunya fever. A mean follow-up of two years. <i>Joint Bone Spine</i> , 2009, 76, 654-657.	0.8	135

#	ARTICLE	IF	CITATIONS
217	Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: A decision tree for clinical practice based on rheumatologists' preferences. <i>Arthritis and Rheumatism</i> , 2009, 61, 425-434.	6.7	21
218	Rheumatoid arthritis after Chikungunya fever: a prospective follow-up study of 21 cases: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1505-1506.	0.5	53
219	Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). <i>Rheumatology</i> , 2009, 48, 425-432.	0.9	67
220	Determining a low disease activity threshold for decision to maintain disease-modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2009, 11, R157.	1.6	5
221	Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort. <i>Arthritis Research and Therapy</i> , 2009, 11, R114.	1.6	62
222	Factors determining a DMARD initiation in early inflammatory arthritis patients. The ESPOIR cohort study. <i>Clinical and Experimental Rheumatology</i> , 2009, 27, 84-91.	0.4	12
223	Maintenance of infliximab treatment in ankylosing spondylitis: Results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. <i>Arthritis and Rheumatism</i> , 2008, 58, 88-97.	6.7	126
224	Remission and rheumatoid arthritis: Data on patients receiving usual care in twenty-four countries. <i>Arthritis and Rheumatism</i> , 2008, 58, 2642-2651.	6.7	156
225	Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. <i>Arthritis and Rheumatism</i> , 2008, 58, 3319-3329.	6.7	539
226	Ability of oblique foot radiographs to detect erosions in early arthritis: Results in the ESPOIR cohort. <i>Arthritis and Rheumatism</i> , 2008, 59, 1729-1734.	6.7	27
227	Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study. <i>Arthritis Research and Therapy</i> , 2008, 10, R106.	1.6	99
228	Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. <i>Arthritis Research and Therapy</i> , 2008, 10, R30.	1.6	387
229	Update on the use of etanercept across a spectrum of rheumatoid disorders. <i>Biologics: Targets and Therapy</i> , 2008, 2, 165.	3.0	10
230	Radiological damage in patients with rheumatoid arthritis on sustained remission. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 358-363.	0.5	106
231	Artritis reumatoide: clínica y diagnóstico. <i>EMC - Aparato Locomotor</i> , 2007, 40, 1-17.	0.1	1
232	Diagnostic du rhumatisme psoriasique de forme psoriasique : élaboration de recommandations pour la pratique clinique, À partir d'une analyse systématique de la littérature et de l'opinion d'experts. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2007, 74, 15-22.	0.0	4
233	Pronostic et suivi du rhumatisme psoriasique de forme psoriasique : élaboration de recommandations pour la pratique clinique, À partir d'une analyse systématique de la littérature et de l'opinion d'experts. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2007, 74, 23-30.	0.0	0
234	Les traitements médicamenteux (hors biothérapie) dans la prise en charge de patients atteints de rhumatisme psoriasique psoriasique : élaboration de recommandations pour la pratique clinique, À partir d'une analyse systématique de la littérature et de l'opinion d'experts. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2007, 74, 31-38.	0.0	0

#	ARTICLE	IF	CITATIONS
235	Early rheumatoid arthritis: strategies for prevention and management. Best Practice and Research in Clinical Rheumatology, 2007, 21, 27-42.	1.4	79
236	Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6months' first-line DMARD therapy. Joint Bone Spine, 2007, 74, 73-78.	0.8	15
237	Imaging for the diagnosis and follow-up of ankylosing spondylitis: Development of recommendations for clinical practice based on published evidence and expert opinion. Joint Bone Spine, 2007, 74, 338-345.	0.8	16
238	Clinical and laboratory follow-up for treating and monitoring patients with ankylosing spondylitis: Development of recommendations for clinical practice based on published evidence and expert opinion. Joint Bone Spine, 2007, 74, 330-337.	0.8	18
239	Pharmacotherapy (excluding biotherapies) for ankylosing spondylitis: Development of recommendations for clinical practice based on published evidence and expert opinion. Joint Bone Spine, 2007, 74, 346-352.	0.8	16
240	The ESPOIR cohort: A ten-year follow-up of early arthritis in France. Joint Bone Spine, 2007, 74, 440-445.	0.8	161
241	Recommendations of the French Society for Rheumatology regarding TNF± antagonist therapy in patients with rheumatoid arthritis. Joint Bone Spine, 2007, 74, 627-637.	0.8	70
242	Recommendations of the French Society for Rheumatology regarding TNF± antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. Joint Bone Spine, 2007, 74, 638-646.	0.8	98
243	Arbre d'Écisionnel permettant leChoix enÉ pratique clinique d'un traitement deÉfond deÉseconde intention auÉcours deÉlaÉpolyarthrite rhumatoÉ de rÉcente, aprÉs Échec d'un traitement deÉfond deÉpremiÉre intention d'une durÉe deÉsixÉmois. Revue Du Rhumatisme (Edition Francaise), 2007, 74, 79-84.	0.0	0
244	Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis. Arthritis Research and Therapy, 2006, 8, R40.	1.6	71
245	EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCSIT). Annals of the Rheumatic Diseases, 2006, 66, 34-45.	0.5	651
246	Methotrexate therapy forÉrheumatoid arthritis: clinical practice guidelines based onÉpublished evidence andÉexpert opinion. Joint Bone Spine, 2006, 73, 388-395.	0.8	126
247	Nonpharmacological treatments inÉearly rheumatoid arthritis: clinical practice guidelines based onÉpublished evidence andÉexpert opinion. Joint Bone Spine, 2006, 73, 396-402.	0.8	58
248	Cardiovascular risk andÉrheumatoid arthritis: clinical practice guidelines based onÉpublished evidence andÉexpert opinion. Joint Bone Spine, 2006, 73, 379-387.	0.8	75
249	TNF± antagonist therapy inÉankylosing spondylitis andÉpsoriatic arthritis: recommendations ofÉtheÉFrench Society forÉRheumatology. Joint Bone Spine, 2006, 73, 547-553.	0.8	31
250	Recommendations ofÉtheÉFrench Society forÉRheumatology. TNF± antagonist therapy inÉrheumatoid arthritis. Joint Bone Spine, 2006, 73, 433-441.	0.8	49
251	Leflunomide combined with conventional disease-modifying antirheumatic drugs orÉbiologics inÉpatients with rheumatoid arthritis. Joint Bone Spine, 2006, 73, 587-590.	0.8	4
252	Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis and Rheumatism, 2006, 54, 2807-2816.	6.7	354

#	ARTICLE	IF	CITATIONS
253	Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1357-1362.	0.5	102
254	Physical examination and laboratory tests in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2005, 72, 222-228.	0.8	43
255	Structural evaluation in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2005, 72, 229-234.	0.8	32
256	How to predict prognosis in early rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 137-146.	1.4	81
257	Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Induces Rheumatoid Arthritis Synovial Fibroblast Proliferation through Mitogen-activated Protein Kinases and Phosphatidylinositol 3-Kinase/Akt. <i>Journal of Biological Chemistry</i> , 2005, 280, 15709-15718.	1.6	152
258	Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 913-920.	0.5	349
259	Tumour necrosis factor α blocking agents in refractory adult Still's disease: an observational study of 20 cases. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 262-266.	0.5	193
260	The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2005, 23, 795-800.	0.4	45
261	Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 675-680.	0.5	105
262	L'Évaluation clinique et biologique dans la prise en charge de personnes souffrant de polyarthrite rhumatoïde de établissement de recommandations pour la pratique clinique à partir de données de la littérature et d'opinions d'experts (Rencontres d'experts en rhumatologie). <i>Revue Du Rhumatisme (Edition Française)</i> , 2004, 71, S127-S136.	0.0	2
263	Switching between anti-TNF α agents: what is the evidence?. <i>Joint Bone Spine</i> , 2004, 71, 169-171.	0.8	17
264	Should patients with recent-onset polyarthritis receive aggressive treatment?. <i>Joint Bone Spine</i> , 2004, 71, 475-480.	0.8	25
265	Faut-il traiter de façon agressive une polyarthrite déformante ?. <i>Revue Du Rhumatisme (Edition Française)</i> 1 0.784314 rgBT ₀ /Overlo	0.0	0
266	Immunopathologie de la arthriti reumatoide. <i>EMC - Aparato Locomotor</i> , 2004, 37, 1-9.	0.1	0
267	Enquête naturaliste sur l'utilisation des anti-inflammatoires non stéroïdiens chez des patients souffrant de douleurs rhumatologiques. <i>Revue Du Rhumatisme (Edition Française)</i> , 2003, 70, 416-423.	0.0	2
268	Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 120-126.	0.5	382
269	Predictive factors of 5-year health assessment questionnaire disability in early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2003, 30, 2344-9.	1.0	72
270	The French early arthritis registry. <i>Clinical and Experimental Rheumatology</i> , 2003, 21, S123-8.	0.4	7

#	ARTICLE	IF	CITATIONS
271	Bone Mineral Density of 704 Amateur Sportsmen Involved in Different Physical Activities. Osteoporosis International, 2001, 12, 152-157.	1.3	125
272	Prognostic factors for radiographic damage in early rheumatoid arthritis: A multiparameter prospective study. Arthritis and Rheumatism, 2001, 44, 1736-1743.	6.7	239
273	Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. Journal of Rheumatology, 2001, 28, 173-81.	1.0	61
274	Anti-heat shock protein 70 kDa and 90 kDa antibodies in serum of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 1999, 58, 291-296.	0.5	78
275	Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Annals of the Rheumatic Diseases, 1999, 58, 220-225.	0.5	227
276	Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. Journal of Rheumatology, 1999, 26, 7-13.	1.0	182
277	Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 1998, 57, 110-113.	0.5	93
278	Polymorphism of the HLA-DMA and DMB genes in Rheumatoid Arthritis. Arthritis and Rheumatism, 1997, 40, 854-858.	6.7	28
279	SULPHASALAZINE IN PSORIATIC ARTHRITIS: A RANDOMIZED, MULTICENTRE, PLACEBO-CONTROLLED STUDY. Rheumatology, 1996, 35, 664-668.	0.9	89
280	PROGNOSTIC FACTORS IN RHEUMATOID ARTHRITIS. COMPARATIVE STUDY OF TWO SUBSETS OF PATIENTS ACCORDING TO SEVERITY OF ARTICULAR DAMAGE. Rheumatology, 1995, 34, 529-534.	0.9	65
281	Increased percentage of cd3+, cd57+ lymphocytes in patients with rheumatoid arthritis. correlation with duration of disease. Arthritis and Rheumatism, 1993, 36, 608-612.	6.7	58
282	Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis. Journal of Rheumatology, 1993, 20, 1129-32.	1.0	79
283	Regression of an expanded subpopulation of large granular lymphocytes in a patient with rheumatoid arthritis. Arthritis and Rheumatism, 1991, 34, 246-247.	6.7	7
284	Treatment of rheumatoid arthritis with methotrexate: a prospective open longterm study of 191 cases. Journal of Rheumatology, 1991, 18, 1323-7.	1.0	52
285	Rheumatoid nodulosis: report of two new cases and discussion of diagnostic criteria. Journal of Rheumatology, 1988, 15, 1427-30.	1.0	36
286	Interleukin-2 in rheumatoid arthritis: production of and response to interleukin-2 in rheumatoid synovial fluid, synovial tissue and peripheral blood. Clinical and Experimental Immunology, 1985, 59, 520-8.	1.1	148